|Articles|February 15, 2002
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
The Immunogenicity of Therapeutic Proteins
Author(s)Fiona Adair, Daniel Ozanne
By Fiona Adair and Daniel Ozanne,Biovation Ltd., pp. 30-36. Immunogenicity is often a barrier to further development of potentially therapeutic proteins. That barrier often remains unknown until late in the development chain. The authors explore various strategies for preventing immunogenicity and for predicting it earlier in the process.
Advertisement
Articles in this issue
over 23 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementover 23 years ago
Inside Washington: Costs and Controls Challenge Manufacturersover 23 years ago
21 CFR Part 11: (Un)Expected Added ValueNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
